Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1991 2
1992 1
1993 2
1995 4
1996 2
1997 3
1998 4
1999 12
2000 5
2001 5
2002 9
2003 8
2004 11
2005 11
2006 10
2007 11
2008 16
2009 24
2010 22
2011 14
2012 20
2013 24
2014 18
2015 26
2016 38
2017 41
2018 26
2019 29
2020 25
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

377 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Lancet Diabetes Endocrinol. 2019. PMID: 31422062
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (088, 083-095; p=0001), hospital admission for heart failure by 9% (091, 083-099; p=0028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtrati …
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (088, 083-095; p=0001), hospital admission for heart failure by 9% (091, …
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Rawshani A, et al. N Engl J Med. 2017 Apr 13;376(15):1407-1418. doi: 10.1056/NEJMoa1608664. N Engl J Med. 2017. PMID: 28402770 Free article.
Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75 …
Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to …
Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B. Zhou Z, et al. Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009. Stroke. 2019. PMID: 30591006 Free PMC article. Clinical Trial.
Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74-1.22), a significant reduction for hemorrhagic stroke (n=30, hazard ratio, 0.43; 95% CI, 0.20-0.89) and no effect on undetermined stroke (n=29, hazard ratio, 1.04; 95% C …
Analysis of stroke subtypes found no effect on ischemic stroke (n=253, hazard ratio, 0.95; 95% CI, 0.74-1.22), a significant reduction
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Htay T, et al. Curr Cardiol Rep. 2019 Apr 22;21(6):45. doi: 10.1007/s11886-019-1133-9. Curr Cardiol Rep. 2019. PMID: 31011838 Review.
PURPOSE OF REVIEW: The aims of this review are to summarize recent data on mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine the interventions that could have contributed to a reduction in mortality. RECENT FINDINGS: Recent studies f …
PURPOSE OF REVIEW: The aims of this review are to summarize recent data on mortality and cardiovascular disease (CVD) in type 1 and type 2 d …
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disea …
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-gluco …
Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis.
He X, Li J, Wang B, Yao Q, Li L, Song R, Shi X, Zhang JA. He X, et al. Endocrine. 2017 Mar;55(3):712-731. doi: 10.1007/s12020-016-1168-2. Epub 2016 Nov 12. Endocrine. 2017. PMID: 27837440 Review.
Subgroup analyses of studies with longer duration of follow-up (1.5 years) or larger sample size (300) also found a significant effect of diabetes self-management education in reducing mortality risk among type 2 diabetes. Significant effect of diabetes self-management edu …
Subgroup analyses of studies with longer duration of follow-up (1.5 years) or larger sample size (300) also found a significant effect of di …
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. Inzucchi SE, et al. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4. Diabetes Care. 2018. PMID: 29203583 Clinical Trial.
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS: Effects of potential mediators, identified post hoc, on the H …
This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to C …
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
INTERPRETATION: Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current standard care for the prevention of a composite of coronary events, cerebrovascular events, and all-cause mortality. Nevertheless, our fin …
INTERPRETATION: Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current stand …
377 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page